Unknown

Dataset Information

0

CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.

ABSTRACT: The prognostic value of CpG island methylator phenotype (CIMP) in colorectal cancer remains unsettled. We aimed to assess the prognostic value of this phenotype analyzing a total of 1126 tumor samples obtained from two Norwegian consecutive colorectal cancer series. CIMP status was determined by analyzing the 5-markers CAGNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 by quantitative methylation specific PCR (qMSP). The effect of CIMP on time to recurrence (TTR) and overall survival (OS) were determined by uni- and multivariate analyses. Subgroup analyses were conducted according to MSI and BRAF mutation status, disease stage, and also age at time of diagnosis (<60, 60-74, ?75 years). Patients with CIMP positive tumors demonstrated significantly shorter TTR and worse OS compared to those with CIMP negative tumors (multivariate hazard ratio [95% CI] 1.86 [1.31-2.63] and 1.89 [1.34-2.65], respectively). In stratified analyses, CIMP tumors showed significantly worse outcome among patients with microsatellite stable (MSS, P?

SUBMITTER: Vedeld HM 

PROVIDER: S-EPMC5518206 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.

Vedeld Hege Marie HM   Merok Marianne M   Jeanmougin Marine M   Danielsen Stine A SA   Honne Hilde H   Presthus Gro Kummeneje GK   Svindland Aud A   Sjo Ole H OH   Hektoen Merete M   Eknaes Mette M   Nesbakken Arild A   Lothe Ragnhild A RA   Lind Guro E GE  

International journal of cancer 20170602 5

The prognostic value of CpG island methylator phenotype (CIMP) in colorectal cancer remains unsettled. We aimed to assess the prognostic value of this phenotype analyzing a total of 1126 tumor samples obtained from two Norwegian consecutive colorectal cancer series. CIMP status was determined by analyzing the 5-markers CAGNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 by quantitative methylation specific PCR (qMSP). The effect of CIMP on time to recurrence (TTR) and overall survival (OS) were determined b  ...[more]

Similar Datasets

Unknown Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
| S-EPMC4622530 | biostudies-other
Unknown Unique DNA methylome profiles in CpG island methylator phenotype colon cancers.
| S-EPMC3266035 | biostudies-literature
Unknown Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype-negative colon cancer.
| S-EPMC4019504 | biostudies-literature
Unknown The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.
| S-EPMC4170521 | biostudies-literature
Unknown Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas.
| S-EPMC3418891 | biostudies-literature
Unknown IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53.
| S-EPMC2134905 | biostudies-literature
Unknown Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype.
| S-EPMC2719983 | biostudies-literature
Unknown Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.
| S-EPMC3749584 | biostudies-literature
Unknown CpG island methylator phenotype predicts progression of malignant melanoma.
| S-EPMC2703821 | biostudies-literature
Unknown Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies.
| S-EPMC7952756 | biostudies-literature